Disease

subcutaneous panniculitis-like T-cell lymphoma

Active therapeutic pipeline

Also known as SPTCL, subcutaneous panniculitic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma (Alpha/Beta type), subcutaneous panniculitis-like T-cell lymphoma, Alpha/Beta type+1 more

SPTCL, subcutaneous panniculitic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma (Alpha/Beta type), subcutaneous panniculitis-like T-cell lymphoma, Alpha/Beta type, T-CELL LYMPHOMA, SUBCUTANEOUS PANNICULITIS-LIKE.

Clinical trials

Associated genes

Related proteins

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low

Key developments

1 clinical trial expected to report results, the earliest in Q4 2026.

Upcoming Milestones

Q4 2026A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Major developments

Major trial resultsHigh impact

A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas

Results posted2026-05-26

Upcoming trial readoutImportant

A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Results expected Q4 20262026-06-17

Clinical Milestones3View

Results posted 1

2026-05-26A Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell LymphomasResults posted

Results expected 1

2026-06-17A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasResults expected Q4 2026

Other updates 1

2029-03-01Phase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)Withdrawn

Activity timeline3

2029-03-01ClinicalPhase II Study of Brentuximab Vedotin in Combination With Pembrolizumab in Patients With Recurrent Systemic Peripheral T-Cell Lymphoma (PTCL)Withdrawn
2026-06-17ClinicalA Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic LymphomasResults expected Q4 2026
2026-05-26ClinicalA Phase 1/2 Study of Pembrolizumab Plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell LymphomasResults posted

Clinical trials

4 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Recruiting

Phase 1/2 · Recruiting · Dren Bio

Recently completed

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in T and NK-Cell Lymphomas

Phase 1 · Completed · National Cancer Institute (NCI)

Associated genes

3 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

HAVCR20.75 RWDD10.04 FAM234B0.03

Disease biology

1 match

Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.

Hepatitis A virus cellular receptor 2via HAVCR20.75

Reference

Authoritative identity, definition & identifiers.

Synonyms

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Related entities are derived from literature co-mention (studied together) — associative, not causal.